Skip to main content
  1. Home
  2. News

Moderna says early coronavirus vaccine results are promising

Georgina Torbet
By

Biotechnology company Moderna has announced the first results from its Phase 1 trial of a vaccine for the coronavirus, showing that a small number of participants developed antibodies to the virus after treatment.

A Phase 1 trial is a small trial of typically around 10 to 20 people that tests whether a potential new treatment is safe and whether it shows signs of its intended effects. Moderna has released the results of the first 8 participants whose data has been analyzed, and they show that the vaccine appears to be safe and not have any serious negative effects.

Recommended Videos

The vaccine appeared to increase the production of antibodies, which are the body’s natural defenses against viruses like the coronavirus. The data which were shared covered two groups of participants who were given two shots each of the vaccine at two different doses, and it appeared to be effective at both the lower and higher dose.

Related

As exciting as these results are, they are still a long way from definitive and from the development of a usable vaccine. Moderna still needs to analyze the rest of the data from the Phase 1 trial. Then, the next stage of vaccine development, which Moderna is currently running, is a Phase 2 trial in which a larger group, comprising hundreds of participants, receive the treatment to see how well it works and whether there are any side effects. The researchers can use the data from this Phase 1 trial to hone in on the dose for this Phase 2 trial.

Cambridge Biotech Moderna Leads in Race For Coronavirus Vaccine
Boston Globe / Getty Images

After that comes the Phase 3 trial, which involves hundreds or thousands of participants to check whether the vaccine is effective and safe for a broader group of people.

If all the preceding stages work out well, the Phase 3 trial set to being in July this year, according to Stéphane Bancel, Chief Executive Officer at Moderna. “The Moderna team continues to focus on moving as fast as safely possible to start our pivotal Phase 3 study in July and, if successful, file a BLA [Biologics License Application, a submission for FDA approval],” Bancel said. “We are investing to scale up manufacturing so we can maximize the number of doses we can produce to help protect as many people as we can from SARS-CoV-2.”

For the latest updates on the novel coronavirus outbreak, visit the World Health Organization’s COVID-19 page.

Editors' Recommendations

Topics
Georgina Torbet
Georgina Torbet
Space Writer
Georgina is the Digital Trends space writer, covering human space exploration, planetary science, and cosmology. She…
How to sign up for a coronavirus vaccine trial
Cambridge Biotech Moderna Leads in Race For Coronavirus Vaccine

With the race to develop a coronavirus vaccine heating up, clinical studies around the U.S are looking for willing participants to help them complete various stages of their research. Tech conglomerates Moderna, AstraZeneca, Johnson & Johnson, and Novavax are all in various stages of human trials, each of which requires hundreds of volunteers. So how does one sign up for a vaccine trial?
How to sign up for a coronavirus trial
While the words "scientific trial" may bring up images of mad scientists, the average clinical study is an important part of the vaccine development process. After methods prove hopeful in laboratories, researchers then perform several detailed studies with humans, to perfect the product. To speed up trial involvement for a coronavirus vaccine, the U.S. National Institute of Health has launched an online public network that connects possible volunteers with hundreds of research facilities across the U.S.

But a lot still has to happen before scientists can stick you with a needle. Possible volunteers must be 18 years or older, and must fill out a volunteer screening history. Signing up for the database takes less than 10 minutes, and will automatically connect users with the trial closest to them.

Read more
Fauci ‘cautiously optimistic’ we will have a coronavirus vaccine this year
gloved hands holding coronavirus test tube stylized image

Dr. Anthony Fauci told a House panel he is "cautiously optimistic" that a coronavirus vaccine will be developed this year.

“We hope that as the time we get into the late fall and early winter we will have, in fact, a vaccine that we can say would be safe and effective,” Fauci, the Director of the National Institute of Allergy and Infectious Diseases, testified before a Democrat led-panel on the outbreak on Friday, July 31. “One can never guarantee the safety or effectiveness unless you do the trial, but we are cautiously optimistic.”

Read more
Bill Gates: U.S. coronavirus response is ‘one of the worst’ in the world
bill gates concerned

Microsoft founder Bill Gates criticized how the U.S. has handled the coronavirus in an interview Wednesday, July 22, condemning the politicization of face masks and moves by the Trump administration to limit the Centers for Disease Control and Prevention (CDC) from sharing data.

“By almost every measure, the U.S. is one of the worst, and I think we can change that but it’s an ugly picture,” he said during an interview with CBS, adding that the politicization of face masks is one of the reasons we are doing worse than other countries.

Read more